LY9 and type 2 diabetes mellitus: Because SLAMF3 has been shown to work as a costimulatory molecule in the activation of human T cells15, we hypothesized that upregulated SLAMF3 expression on T cells may contribute to the persistent “low-grade inflammatory” status of T2D patients.